Compare RELL & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | RPID |
|---|---|---|
| Founded | 1947 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.6M | 178.6M |
| IPO Year | N/A | 2021 |
| Metric | RELL | RPID |
|---|---|---|
| Price | $10.97 | $3.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 52.9K | ★ 104.8K |
| Earning Date | 01-06-2026 | 11-07-2025 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $209,791,000.00 | $30,523,000.00 |
| Revenue This Year | $4.72 | $19.36 |
| Revenue Next Year | $14.93 | $21.48 |
| P/E Ratio | $903.34 | ★ N/A |
| Revenue Growth | 6.17 | ★ 16.63 |
| 52 Week Low | $7.57 | $0.87 |
| 52 Week High | $15.51 | $4.50 |
| Indicator | RELL | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 57.20 | 45.96 |
| Support Level | $10.75 | $3.78 |
| Resistance Level | $11.47 | $4.07 |
| Average True Range (ATR) | 0.42 | 0.21 |
| MACD | 0.11 | -0.08 |
| Stochastic Oscillator | 75.00 | 20.93 |
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.